, Union Européenne. Parlement européen, RÈGLEMENT 2017/745 du 5 avril 2017 relatif aux dispositifs médicaux
, Panorama de la filière industrielle des dispositifs médicaux en France en 2017, 2018.
Pôle interministériel de prospective et d'anticipation des mutations économiques -PIPAME. Dispositifs médicaux : diagnostic et potentialités de développement de la filière française dans la concurrence internationale, 2011. ,
Rapport du 8ème Conseil stratégique des industries de santé (CSIS), Juillet, 2018. ,
, Laboratoire national de métrologie et d'essais. Rapport d'activité, 2018.
Loi n° 2003-1199 du 18 décembre 2003 de financement de la sécurité sociale pour, 2004. ,
Ministère de l'action et des comptes publics. Arrêté du 6 mars 2019 fixant pour l'année 2019 les éléments tarifaires mentionnés aux I et ,
Direction générale de l'offre de soins. INSTRUCTION N° DGOS/R1/2019/55 du 14 mars 2019 relative aux coefficients applicables aux tarifs des établissements de santé mentionnés au d) ,
Ministère de la santé ,
Rapport d'information : Industrie du médicament : mettre la fiscalité en perspective, 2007. ,
Arrêté du 27 avril 2017 relatif au contrat type d'amélioration de la qualité et de l'efficience des soins mentionné à l'article L. 162-30-2 du code de la sécurité sociale ,
, Haute Autorité de la santé, Service des bonnes pratiques professionnelles
, Niveau de preuve et gradation des recommandations de bonne pratique, 2013.
, KEwj_laSW_pjkAhVkqnEKHXZyDbwQFjAAegQIAxAC&url=https%3A%2F%2Fw ww.has-sante.fr%2Fupload%2Fdocs%2Fapplication%2Fpdf%2F2013
Medical device assessment: scientific evidence examined by the French national agency for health -a descriptive study, BMC Public Health, vol.12, p.585, 2012. ,
Need for a National Evaluation System for Health Technology, JAMA, vol.316, issue.11, pp.1153-1157, 2016. ,
Scientific evaluation and pricing of medical devices and associated procedures in France, Therapie, vol.68, issue.4, pp.193-208, 2013. ,
Medical device specificities: opportunities for a dedicated product development methodology, Expert Rev Med Devices, vol.9, issue.3, pp.299-311, 2012. ,
,
Int J Technol Assess Health Care, vol.33, pp.605-608, 2017. ,
Health technology assessment of medical devices: What is different? An overview of three European projects, Z Evid Fortbild Qual Gesundhwes, vol.109, issue.4-5, pp.309-327, 2015. ,
Five year trends (2008-2012) in cardiac implantable electrical device utilization in five European nations: a case study in crosscountry comparisons using administrative databases, Europace, vol.20, issue.4, pp.643-653, 2018. ,
Health technology assessment of medical devices in europe: processes, practices, and methods. Int J Technol Assess Health Care, vol.32, pp.246-255, 2016. ,
Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies, Int J Epidemiol, vol.43, issue.4, pp.1272-1283, 2014. ,
,
,
Estimating the Learning Curve of a Novel Medical Device: Bipolar Sealer Use in Unilateral Total Knee Arthroplasties, Economic Evaluation, vol.21, pp.283-94, 2018. ,
Proctors in interventional cardiology: go beyond mentoring and monitoring! Heart Asia, vol.9, p.10953, 2017. ,
Inclusion of Training Patients in US Food and Drug Administration Premarket Approval Cardiovascular Device Studies, Arch Intern Med, vol.171, issue.6, pp.534-539, 2011. ,
Learning curve estimation in medical devices and procedures: hierarchical modeling, vol.36, pp.2764-2785, 2017. ,
Prevolnik Rupel V. Improving the Methods for the Economic Evaluation of Medical Devices. Health Econ, vol.26, pp.70-92, 2017. ,
Key Recommendations from the MedtecHTA Project. Health Econ, vol.26, pp.145-152, 2017. ,
,
, Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs. Health Econ, vol.26, pp.109-123, 2017.
Are Standard Dosing Regimens of ,
, Ceftriaxone Adapted for Critically Ill Patients with Augmented Creatinine Clearance? Antimicrob Agents Chemother, vol.63, 2019.
, Chapitre VIII : La fixation du prix des médicaments : des résultats significatifs, des enjeux toujours majeurs d'efficience et de soutenabilité, un cadre d'action à fortement rééquilibrer, Cours des comptes. Rapport Sécurité sociale 2017
, KEwjpmb3miZnkAhXZTxUIHTO8DJsQFjABegQIBRAC&url=https%3A%2F%2Fw ww.ccomptes.fr%2Fsites%2Fdefault%2Ffiles%2F2017-09%2F20170920-rapportsecurite-sociale-2017-fixation-prixmedicaments
Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation, N Engl J Med, vol.379, issue.24, pp.2297-2306, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02003312
, Avis relatif à la tarification de MITRACLIP et MITRACLIP NT visés à l'article L. 165-1 du code de la sécurité sociale
Direction générale de l'offre de soins ,
,
Nonsustained ventricular tachycardia, J Am Coll Cardiol, vol.60, issue.20, pp.1993-2004, 2012. ,
Epidemiology and Genetics of Sudden Cardiac Death, Circulation, vol.125, issue.4, pp.620-637, 2012. ,
,
Scan santé ,
Incidence of Idiopathic Ventricular Arrhythmias, Circ Arrhythm Electrophysiol, vol.10, issue.2, 2017. ,
Epidemiology of Sudden Cardiac Death: Clinical and Research Implications, Prog Cardiovasc Dis, vol.51, issue.3, pp.213-228, 2008. ,
Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy, Eur Heart J, vol.30, issue.21, pp.2599-605, 2009. ,
The management of clinical arrhythmias. An overview on invasive versus non-invasive electrophysiology, Eur Heart J, vol.8, pp.92-101, 1987. ,
Rhythmical pulsation in scyphomedusae ,
, Carnegie Institution of Washington Publication, p.47, 1906.
Pathophysiology of ventricular tachyarrhythmias : From automaticity to reentry, Herzschrittmacherther Elektrophysiol, vol.28, issue.2, pp.149-156, 2017. ,
On dynamic equilibrium in the heart, J Physiol, vol.46, pp.349-82, 1913. ,
Pathophysiology of ventricular tachyarrhythmias : From automaticity to reentry, Herzschrittmacherther Elektrophysiol, vol.28, issue.2, pp.149-156, 2017. ,
Idiopathic recurrent sustained ventricular tachycardia responsive to verapamil: an ECGelectrophysiologic entity, Am Heart J, vol.198, issue.4Pt1, pp.1034-1041, 1983. ,
Ventricular tachycardia in ischemic heart disease substrates, Indian Heart J, pp.66-90, 2014. ,
The Pathogenesis of Cardiac Fibrosis, Cell Mol Life Sci, vol.71, issue.4, pp.549-574, 2014. ,
Macroreentry in the infarcted human heart: the mechanism of ventricular tachycardias with a "focal" activation pattern, J Am Coll Cardiol, vol.18, issue.4, pp.1005-1019, 1991. ,
,
, Ventricular Tachycardia Circuits Using Ultra-High-Density Mapping, Circ Arrhythm Electrophysiol, vol.11, issue.10, p.6569, 2018.
Hypertrophic cardiomyopathy. Lancet, vol.381, pp.242-55, 2013. ,
Arrhythmogenic Right Ventricular Cardiomyopathy, N Engl J Med, vol.376, issue.1, pp.61-72, 2017. ,
AHA/ACC/HRS cardiac death: Executive summary: A Report of the American College of, 2017. ,
Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society, Heart Rhythm, vol.15, issue.10, pp.190-252, 2018. ,
, Med Clin North Am, 2019.
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial, JAMA, vol.295, issue.2, pp.165-71, 2006. ,
Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. Cochrane Database Syst Rev, 2015. ,
Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone, Drug Metab Dispos, vol.43, issue.2, pp.182-191, 2015. ,
Clinical pharmacokinetics of amiodarone, Clin Pharmacokinet, vol.9, issue.2, pp.136-56, 1984. ,
, J Cardiovasc Electrophysiol, vol.14, issue.9, 2003.
The MUSTT study: evaluating testing and treatment, J Interv Card Electrophysiol, vol.4, issue.1, pp.45-50, 2000. ,
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction, N Engl J Med, vol.346, issue.12, pp.877-83, 2002. ,
Comparison of arrhythmia recurrence in patients presenting with ventricular fibrillation versus ventricular tachycardia in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial, Am J Cardiol, 2003. ,
, Apr, vol.1, issue.7, pp.812-818
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone, Circulation, vol.101, issue.11, pp.1297-302, 2000. ,
Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH), Circulation, vol.102, issue.7, pp.748-54, 2000. ,
Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT): a randomized clinical trial, Circulation, vol.107, issue.17, pp.2221-2227, 2003. ,
Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation, Health Technol Assess, vol.18, issue.56, pp.1-560, 2014. ,
Inappropriate Shock Delivered By ,
, Implantable Cardioverter Defibrillator -Cardiac Resynchronization Therapy (ICD-CRT) Due To Myopotential Oversensing, Indian Pacing Electrophysiol J, 2009.
Combining shock reduction strategies to enhance ICD therapy: a role for computer modeling, J Cardiovasc Electrophysiol, vol.22, issue.3, pp.280-289, 2011. ,
Reduction in inappropriate therapy and mortality through ICD programming, N Engl J Med, vol.367, issue.24, pp.2275-83, 2012. ,
Sudden cardiac death in heart failure trial (SCD-HeFT) investigators. Amiodarone or/and implantable cardioverter defibrillator for congestive heart failure, N Engl J Med, vol.352, pp.225-262, 2005. ,
Low inappropriate shock rates in patients with single-and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results, Heart Rhythm, vol.12, issue.5, pp.926-962, 2015. ,
Prophylactic Catheter Ablation for the Prevention of Defibrillator Therapy, N Engl J Med, vol.357, issue.26, pp.2657-2665, 2007. ,
Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial, Circulation, vol.118, issue.25, pp.2773-82, 2008. ,
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs, N Engl J Med, vol.375, issue.2, pp.111-132, 2016. ,
Image Integration to Guide Catheter Ablation in Scar-Related Ventricular Tachycardia, J Cardiovasc Electrophysiol, vol.27, issue.6, pp.699-708, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01936715
Are wall thickness channels defined by computed tomography predictive of isthmuses of postinfarction ventricular tachycardia? Heart Rhythm, 2019. ,
Long-Term Outcome of Substrate Modification in Ablation of Post-Myocardial Infarction Ventricular Tachycardia, Circ Arrhythm Electrophysiol, vol.11, issue.2, p.5635, 2018. ,
Epicardial ventricular tachycardia ablation a multicenter safety study, J Am Coll Cardiol, vol.55, issue.21, pp.2366-72, 2010. ,
Multielectrode vs. point-by-point mapping for ventricular tachycardia substrate ablation: a randomized study, Europace, vol.20, issue.3, pp.512-519, 2018. ,
Endocardial Versus Epicardial Ventricular Radiofrequency Ablation, Circ Arrhythm Electrophysiol, vol.6, issue.1, pp.144-50, 2013. ,
Ablation index, a novel marker of ablation lesion quality: prediction of pulmonary vein reconnection at repeat electrophysiology study and regional differences in target values, Europace, vol.19, issue.5, pp.775-83, 2017. ,
Elimination of local abnormal ventricular activities: a new end point for substrate modification in patients with scar-related ventricular tachycardia, Circulation, vol.125, issue.18, pp.2184-96, 2012. ,
Substrate-guided ablation of haemodynamically tolerated and untolerated ventricular tachycardia in patients with structural heart disease: effect of cardiomyopathy type and acute success on long-term outcome, Europace, vol.17, issue.3, pp.461-468, 2015. ,
Elimination of local abnormal ventricular activities: a new end point for substrate modification in patients with scar-related ventricular tachycardia, Circulation, vol.125, issue.18, pp.2184-96, 2012. ,
Neuraxial modulation for ventricular arrhythmias: a new hope, Heart Rhythm, vol.9, pp.1888-1889, 2012. ,
Choix méthodologiques pour l'évaluation économique à la HAS. Octobre, 2011. ,
Agence technique de l'information sur l'hospitalisation. Etude nationale des coûts, vol.93 ,
Trends and Outcomes of Catheter Ablation for Ventricular Tachycardia in a Community Cohort, JACC Clin Electrophysiol, vol.4, issue.9, pp.1189-1199, 2018. ,
Agence Régionale de Santé Nouvelle Aquitaine. Schéma régional d'organisation des soins, 2018. ,
Strategies for reducing the door-toballoon time in acute myocardial infarction, N Engl J Med, vol.355, pp.2308-2320, 2006. ,
,
Shop for quality or volume? Volume, quality, and outcomes of coronary artery bypass surgery, Ann Intern Med, vol.150, pp.696-704, 2009. ,
Hospital volume and 30-day mortality for three common medical conditions, N Engl J Med, vol.362, issue.12, pp.1110-1118, 2010. ,
Use of health care databases in pharmacoepidemiology, Basic Clin Pharmacol Toxicol, vol.98, issue.3, pp.311-314, 2006. ,
Requests for postregistration studies (PRS), patients follow-up in actual practice: Changes in the role of databases, Therapie, vol.73, pp.13-24, 2018. ,
Catheter ablation of recurrent scarrelated ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: Results of the prospective multicenter Euro-VT-study, J Cardiovasc Electrophysiol, vol.21, issue.1, pp.47-53, 2010. ,
, , vol.of electrophysiologic study
, Circ J, vol.72, issue.2, pp.268-273, 2008.
Refractory ventricular tachycardia secondary to cardiac sarcoid: Electrophysiologic characteristics, mapping, and ablation, Heart Rhythm, vol.3, issue.8, pp.924-929, 2006. ,
Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy, Circ Arrhythm Electrophysiol, vol.4, issue.2, pp.185-194, 2011. ,
Impact of Substrate Modification by ,
, Catheter Ablation on Implantable Cardioverter-Defibrillator Interventions in Patients With Unstable Ventricular Arrhythmias and Coronary Artery Disease: Results From the Multicenter Randomized Controlled SMS (Substrate Modification Study)
, Arrhythm Electrophysiol, vol.10, issue.3, 2017.
Prophylactic catheter ablation of ventricular tachycardia in ischemic cardiomyopathy: a systematic review and metaanalysis of randomized controlled trials, J Interv Card Electrophysiol, vol.53, issue.2, pp.207-215, 2018. ,
Post-Myocardial Infarction Scar With Fat Deposition Shows Specific Electrophysiological Properties and Worse Outcome After Ventricular Tachycardia Ablation, J Am Heart Assoc, vol.8, issue.15, p.12482, 2019. ,
Evaluation des dispositifs médicaux innovants dans les CHU en vue de leur acquisition état des lieux et élaboration d'un outil d'aide à la décision, 2015. ,
Impact of ventricular tachycardia ablation on health care utilization, Heart Rhythm, vol.15, issue.3, pp.355-362, 2018. ,
Health Care Utilization After ,
, Ventricular Tachycardia Ablation: A Propensity Score-Matched Cohort Study, Can J Cardiol, vol.35, issue.2, pp.169-177, 2019.